Jeff Yass’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Jeff Yass’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-46,695	Closed	-$850K	–	13450
2024 Q2	$850K	Buy	46,695 +5,382	+13%	+$98.5K	﹤0.01%	6971
2024 Q1	$761K	Buy	41,313 +7,173	+21%	+$133K	﹤0.01%	7521
2023 Q4	$668K	Buy	34,140 +12,994	+61%	+$227K	﹤0.01%	7960
2023 Q3	$378K	Buy	21,146 +9,209	+77%	+$180K	﹤0.01%	8856
2023 Q2	$246K	Buy	+11,937	New	+$250K	﹤0.01%	9844
2023 Q1	–	Sell	-49,144	Closed	-$1.1M	–	13827
2022 Q4	$1.1M	Buy	49,144 +9,966	+25%	+$225K	﹤0.01%	5967
2022 Q3	$812K	Buy	39,178 +5,303	+16%	+$129K	﹤0.01%	7177
2022 Q2	$788K	Buy	33,875 +20,700	+157%	+$493K	﹤0.01%	7114
2022 Q1	$361K	Buy	+13,175	New	+$371K	﹤0.01%	9809

Other funds holding GERM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jeff Yass's GERM Position: Q3 2024 in Review

Jeff Yass sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2024, closing a stake of 46,695 shares — an estimated $850K sold.

Jeff Yass first reported a position in GERM in Q1 2022 and held it in 9 quarters. The position peaked at $1.1M in Q4 2022. 1 fund tracked by Wall St. Rank holds GERM as of Q3 2024.

Jeff Yass reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2024 after selling out during the quarter.
Jeff Yass sold 46,695 Amplify Treatments, Testing and Advancements ETF shares in Q3 2024, an estimated $850K.
Jeff Yass first reported a position in Amplify Treatments, Testing and Advancements ETF in Q1 2022 and held it in 9 quarters.
Jeff Yass's Amplify Treatments, Testing and Advancements ETF position peaked at $1.1M in Q4 2022.
1 fund tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.